Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBAMo Qatanani, Ph.D.
Chief Scientific Officer, Scholar Rock
- Industry
- Neuromuscular biopharma and rare diseases
- Based in
- Cambridge, USA
- Company funding
- Undisclosed
- Region
- North America
Biopharmaceutical research and development leader.
Leads scientific strategy at Scholar Rock.
Mo Qatanani, Ph.D., is Chief Scientific Officer of Scholar Rock.
More founders in Neuromuscular biopharma and rare diseases
- David L. Hallal
Scholar Rock
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Digital Health Funding Hit $7.4B in H1 2026. Here Is Where the Money Actually Went.
Digital Health Funding Hit $7.4B in H1 2026. Here Is Where the Money Actually Went.
Dr. Dereck Mush, MD, MBA
Inverting the GLP-1 Axis: Antagonism and the Unintended Metabolic Casualties of Bariatric Surgery
Dr. Dereck Mush, MD, MBA
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBAKeep exploring